peptides typeshitSafety
The Times hears from women who got pregnant while taking Mounjaro
One writer shares her own unexpected pregnancy while taking the tirzepatide shot, and says many others have been through the same thing.
peptides
-
The Times hears from women who got pregnant while taking Mounjaro -
Philstar Life on semaglutide and the PIONEER 8 trial peptides typeshitResearchPhilstar Life on semaglutide and the PIONEER 8 trial
A short Philstar Life item on PIONEER 8, a trial of oral semaglutide. The material gives only the title, so tap through for the details.
-
Mushroom peptide ASHGEGF boosts how salty food tastes by about 70% peptides typeshitResearchMushroom peptide ASHGEGF boosts how salty food tastes by about 70%
Gannan Medical University researchers screened 6,000 candidates from Hypsizygus marmoreus and found peptides that may help cut sodium without losing flavor.
-
Health explains the steps to getting a Wegovy prescription and checking coverage peptides typeshitPricesHealth explains the steps to getting a Wegovy prescription and checking coverage
An explainer on talking to a provider about whether Wegovy fits you, plus a reminder that insurance may not pay for it.
-
EU medicines committee recommends Lilly's Foundayo pill for obesity and diabetes 
EU medicines committee recommends Lilly's Foundayo pill for obesity and diabetes
The CHMP opinion from 15 October now goes to the European Commission. In trials, people on the daily orforglipron tablet lost about 5% to 11% of body weight over 72 weeks.
-
Bahrain's NHRA approves Wegovy pills for treating obesity 
Bahrain's NHRA approves Wegovy pills for treating obesity
The country's health regulator has cleared the oral version of Novo Nordisk's semaglutide for weight management.
-
Mochi Health moves to dose-based GLP-1 pricing and launches Mochi Labs bloodwork Mochi Health moves to dose-based GLP-1 pricing and launches Mochi Labs bloodwork
Compounded semaglutide and tirzepatide now cost less at lower starting doses, and members can order cholesterol, A1C and thyroid panels in the same app.
-
Mochi Health cuts compounded semaglutide and tirzepatide prices, adds lab testing Mochi Health cuts compounded semaglutide and tirzepatide prices, adds lab testing
Pricing now scales with dose, so people on lower starting doses pay less. The new Mochi Labs bloodwork service tracks A1C, cholesterol and thyroid, though not in NY, NJ, RI or HI.
-
Eli Lilly posts $22.97B quarter and plans a retatrutide FDA filing in early 2027 
Eli Lilly posts $22.97B quarter and plans a retatrutide FDA filing in early 2027
Revenue rose 48% on Mounjaro and Zepbound demand, and Lilly raised 2026 guidance to $85B to $87B. CEO David Ricks calls retatrutide the next growth driver.
-
Peptide compounders face growing USP 795 and 797 scrutiny from regulators 
Peptide compounders face growing USP 795 and 797 scrutiny from regulators
A pharmacy attorney explains why boards and plaintiffs now treat USP standards as the baseline, and why research use only labels won't shield sloppy compounding.
-
Polskie Radio warns weight-loss drugs like Ozempic are driving a quiet health crisis Polskie Radio warns weight-loss drugs like Ozempic are driving a quiet health crisis
A Polish Radio piece argues that Ozempic and similar weight-loss drugs are creating health problems that get little attention.
-
University of Missouri doctor warns against buying gray-market peptides like BPC-157 
University of Missouri doctor warns against buying gray-market peptides like BPC-157
Dr. Regina DePietro of MU Health Care says unapproved injectables sold "for research" lack safety checks, and the products could be fake or useless.
-
Nutritionist Kim Pearson on keeping weight off after stopping GLP-1 drugs Nutritionist Kim Pearson on keeping weight off after stopping GLP-1 drugs
One semaglutide trial saw about two thirds of lost weight return within a year. Pearson points to protein, strength training, sleep and weekly weigh-ins.
-
Novo Nordisk cuts the price of its weight loss drug Wegovy in China peptides typeshitPricesNovo Nordisk cuts the price of its weight loss drug Wegovy in China
Polskie Radio reports a Wegovy price cut in China, coming soon after the drug's approval there. Tap through for the details.
-
Polskie Radio looks at Mounjaro's FDA approval status for weight loss Polskie Radio looks at Mounjaro's FDA approval status for weight loss
A brief Polskie Radio item on whether Mounjaro is FDA approved for weight loss. Little detail is available beyond the topic itself.
-
Novo Nordisk's experimental drug amycretin shows significant weight loss peptides typeshitResearchNovo Nordisk's experimental drug amycretin shows significant weight loss
Meteo.gr reports strong weight loss results for amycretin, Novo Nordisk's next obesity candidate. Few details were given beyond the headline.
-
Polskie Radio looks at how well the Wegovy pill works for weight loss peptides typeshitResearchPolskie Radio looks at how well the Wegovy pill works for weight loss
An explainer on the effectiveness of oral Wegovy, the daily semaglutide pill. Little detail is available beyond the headline.
-
Eli Lilly lowers the price of its weight loss drug, per a brief report Eli Lilly lowers the price of its weight loss drug, per a brief report
A thin search result says Lilly has cut the price of its weight loss drug. No figures, dates or product names are included.
-
Rutgers study ties GLP-1 drugs to 3 to 4 extra sudden vision loss cases per 10,000 peptides typeshitSafetyRutgers study ties GLP-1 drugs to 3 to 4 extra sudden vision loss cases per 10,000
Researchers looked at U.S. adults with type 2 diabetes starting a GLP-1 and estimate a small added risk of sudden vision loss that is often permanent.
-
Amazon Pharmacy starts offering the new oral Wegovy weight loss pill Amazon Pharmacy starts offering the new oral Wegovy weight loss pill
Novo Nordisk's pill form of Wegovy is now available to order through Amazon Pharmacy, per Polskie Radio. Details on pricing weren't included.
-
NSW Health logs 1,180 emergency visits from unapproved peptide injections peptides typeshitSafetyNSW Health logs 1,180 emergency visits from unapproved peptide injections
Cases climbed from 5 a month to 217 by September 2026, NSW Health figures show. Black-market retatrutide was involved in 71% of the visits.
-
University of Missouri doctor warns against gray-market peptides like BPC-157 University of Missouri doctor warns against gray-market peptides like BPC-157
Dr. Regina DePietro of MU Health Care says unapproved peptides sold for research lack the safety checks Ozempic went through, and suggests asking a doctor first.
-
Novo Nordisk will start selling its weight-loss drug Wegovy in vials Novo Nordisk will start selling its weight-loss drug Wegovy in vials
Novo Nordisk plans to offer Wegovy in vials as well as its usual format. The report gives no timing or pricing yet.
-
Millions of surgery records point to a possible new upside of GLP-1 drugs Millions of surgery records point to a possible new upside of GLP-1 drugs
The study's lead author told Newsweek the team found a benefit that reaches past what GLP-1 drugs are usually known for.
-
Meta-analysis of six CagriSema trials finds similar weight loss at 1 mg and 2.4 mg 
peptides typeshitResearchMeta-analysis of six CagriSema trials finds similar weight loss at 1 mg and 2.4 mg
Pooling 4,805 people with type 2 diabetes, researchers saw about 8% weight loss at both doses, with more stomach side effects and dropouts at 2.4 mg.
-
Orthopedic surgeon Brian Nwannunu on GLP-1 drugs, bones, joints and muscle 
Orthopedic surgeon Brian Nwannunu on GLP-1 drugs, bones, joints and muscle
Knee relief can be big, but muscle and bone loss is a real risk, especially for older adults. He recommends tracking protein and lifting weights.
-
Lilly's retatrutide hits 28.3% average weight loss at top dose in TRIUMPH-1 
peptides typeshitResearchLilly's retatrutide hits 28.3% average weight loss at top dose in TRIUMPH-1
Lilly reports all three doses met their goals at 80 weeks, with about 11% quitting on 12 mg and 13% reporting dysesthesia. Shares rose about 1% premarket.
-
Polskie Radio reports on a new weight-loss drug pitched as an Ozempic replacement Polskie Radio reports on a new weight-loss drug pitched as an Ozempic replacement
Polish public radio covers a new weight-loss medication being talked about as a successor to Ozempic. Details are thin beyond the headline.
-
Polskie Radio on new 2026 weight loss drugs, including retatrutide and CagriSema Polskie Radio on new 2026 weight loss drugs, including retatrutide and CagriSema
Polskie Radio covers the next wave of weight loss drugs, with retatrutide and CagriSema named. Few details were available beyond the topic itself.
-
Philstar Life rounds up the latest 2026 updates on retatrutide Philstar Life rounds up the latest 2026 updates on retatrutide
Philstar Life has a roundup of where Eli Lilly's experimental retatrutide stands in 2026. Specifics were not available here, so tap through for the details.